Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: A retrospective, observational, multicenter study

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 3, 2009, Pages 247-252

  Serrano, Pilar ^a   Justicia, Jośe Luis ^b,e   Sánchez, Cesárea ^c   Cimarra, Mercedes ^d   Fernández Távora, Laureano ^d   Orovitg, Agustín ^d   Moreno, Carmen ^a   Guerra, Francisco ^a   Alvá, Víctor ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b I3 Research   (Spain)

^c Allergy Unit   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e C Ramón Turró   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUSTAL; CALCIUM PHOSPHATE; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; PHOSTAL; POLLEN EXTRACT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; ASTHMA; CHILD; CONTROLLED STUDY; COUGHING; DERMATITIS; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; FLUSHING; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; NAUSEA; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT ALLERGY; RETROSPECTIVE STUDY; RHINITIS; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; STRIDOR; URTICARIA; VOMITING;

EID: 63449084672     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60088-9     Document Type: Article

References (30)

1. Malling HJ, Weeke B. Immunotherapy: position paper of the EAACI. Allergy. 1993;48(suppl 14):9-35.
2. Conh JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol. 1993;91:734-737.
3. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 1993;70:480-482.
4. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol. 2002;88:391-394.
5. Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Safety. 1994;10:5-17.
6. Parmiani S, Fernandez Tavora L, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol (Madr). 2002;30:283-291.
7. Alvarez Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(suppl 82):1-20.
8. The use of the WHO-UMC system for standardised case causality assessment. WHO Collaborating Center for International Drug Monitoring, Uppsala Monitoring Center Web site. http://www.who-umc.org/graphics/4409.pdf. Accessed October 24, 2007.
9. Tabar AI, Fernández Távora L, Alonso R, et al. Tolerance of a cluster schedule with a house dust mite extract quantified in mass unit: multi-centre study. J Invest Allergol Clin Immunol. 2004;14:193-197.
10. Moreno C, Fernández Távora L, Vidal C, Justicia JL, Guerra F. Estudio prospectivo de seguridad de inmunoterapia agrupada con extractos acuosos de pólenes. Alergol Inmunol Clin. 2001;16:95-101.
11. Moreno C, Fernandez Tavora L, Justicia JL, Cabeza N, Vidal C. Investigation of an adequate immunotherapy induction schedule with an Alternaria tenuis extract. Alergol Inmunol Clin. 2001;16:133-137.
12. Moreno C, Cuesta-Herranz J, Fenández-Távora L, Álvarez-Cuesta E. Immunotherapy safety: a prospective multicentric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;34:527-531.
13. Tabar AI, Echechipia S, García BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116: 109-118.
14. Tabar AI, Garcia BE, Rodríguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extract. Allergy. 1993;48:450-453.
15. Tabar AI, Echechip a S, Garíc a BE, et al. Safety-monitoring of allergen-specific immunotherapy with standardized extract: a prospective and predictive study in 7000 patients [abstract]. Allergy. 2001;56(suppl 68):91.
16. Cox L, Li J, Lockey R, Nelson H. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007;120:S25-S85.
17. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97:126-138.
18. Greenberg MA, Kaufman CR, Gonzalez GE, Rosenblatt CD, Smith LJ, Summers RJ. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol. 1986;77:865-870.
19. Matloff SM, Bailit IW, Parks P, Madden N, Greineder DK. Systemic reactions to immunotherapy. Allergy Proc. 1993;14:347-350.
20. Justicia JL, Serrano P, Barasona MJ, et al. Factores de riesgo para la aparición de reacciones sistémicas tardías durante la inmunoterapia agrupada. Alergol Inmunol Clin. 2003;18:178.
21. Mellerup MT, Hahn GW, Poulsen LK, Malling HJ. Safety of allergen-specific immunotherapy: relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30:1423-1429.
22. Cadario G, Marengo F, Ranghino E, et al. Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Investig Allergol Clin Immunol. 2004;14: 127-133.
23. Guardia Martínez P. Seguridad de pautas cluster con pólenes de gramíneas y olivo. http://www.alergoaragon.org/2003/segunda1.html. Accessed January 10, 2008.
24. Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy: a phase-1 study. Allergy. 2006;61:1173-1176.
25. Malling HJ, Lund L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Invest Allergol Clin Immunol. 2006;16:162-168.
26. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117: 169-175.
27. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990 -2001. J Allergy Clin Immunol. 2004;113:1129-1136.
28. Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch and grass pollen allergic rhinitis, II: side-effects. Allergy. 2000; 55:827-835.
29. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004;92:225-227.
30. Tankersley MS, Butler KK, Butler WK, Groetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000;100:840-843.